The scientist’s investigation covers issues in Breast cancer, Oncology, Internal medicine, Cancer and Cancer research. His study on Breast cancer is covered under Genetics. His research in Oncology intersects with topics in Germline mutation, PARP inhibitor, Chemotherapy, Systemic therapy and Pathology.
The Cancer research study combines topics in areas such as Nucleotide excision repair, DNA mismatch repair, DNA repair, DNA repair protein XRCC4 and Homologous Recombination Pathway. His research investigates the connection with DNA repair and areas like Mutation rate which intersect with concerns in DNA Mutational Analysis. Andrew Tutt focuses mostly in the field of DNA repair protein XRCC4, narrowing it down to matters related to Base excision repair and, in some cases, PARP1.
His main research concerns Breast cancer, Internal medicine, Cancer research, Oncology and Cancer. His Breast cancer research includes elements of Clinical trial, Immunology, Metastasis, Disease and Adjuvant therapy. His Internal medicine research integrates issues from Gynecology, Surgery and Pathology.
Andrew Tutt has included themes like Gene, Synthetic lethality, DNA repair, PARP inhibitor and Cancer cell in his Cancer research study. His PARP inhibitor study integrates concerns from other disciplines, such as Iniparib, Olaparib and Poly Polymerase Inhibitor. His biological study spans a wide range of topics, including Radiation therapy and Bioinformatics.
Andrew Tutt focuses on Cancer research, Triple-negative breast cancer, Oncology, Internal medicine and Breast cancer. The concepts of his Cancer research study are interwoven with issues in Cancer cell, Cancer and RAD51, DNA repair, Homologous recombination. His study looks at the relationship between DNA repair and fields such as Rucaparib, as well as how they intersect with chemical problems.
His Oncology research is multidisciplinary, incorporating elements of Carboplatin, Disease, Allele, Docetaxel and Immunotherapy. Many of his research projects under Internal medicine are closely connected to Pandemic, 2019-20 coronavirus outbreak and Severe acute respiratory syndrome coronavirus 2 with Pandemic, 2019-20 coronavirus outbreak and Severe acute respiratory syndrome coronavirus 2, tying the diverse disciplines of science together. He combines subjects such as Clinical trial, MEDLINE, Stromal tumor, Predictive biomarker and Biomarker with his study of Breast cancer.
Andrew Tutt mainly focuses on Cancer research, Poly Polymerase Inhibitor, DNA repair, Rucaparib and Triple-negative breast cancer. His Cancer research study combines topics in areas such as Cancer cell, Cancer, Cell and Lymphatic Endothelium. His work focuses on many connections between Cancer and other disciplines, such as Synthetic lethality, that overlap with his field of interest in Breast cancer.
The various areas that Andrew Tutt examines in his Poly Polymerase Inhibitor study include BRCA2 Protein, Olaparib, Homologous recombination, Triple Negative Breast Neoplasms and PARP1. Andrew Tutt is studying RAD51, which is a component of DNA repair. His study in Triple-negative breast cancer is interdisciplinary in nature, drawing from both Carcinogenesis, T cell, T-cell receptor, CD8 and Cytolysis.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov;Serena Nik-Zainal;Serena Nik-Zainal;David C. Wedge;Samuel A. J. R. Aparicio.
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Hannah Farmer;Nuala McCabe;Christopher J. Lord;Andrew N. J. Tutt;Andrew N. J. Tutt.
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Peter C Fong;David S Boss;Timothy A Yap;Andrew Tutt.
The New England Journal of Medicine (2009)
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
A Goldhirsch;E P Winer;A S Coates;R D Gelber.
Annals of Oncology (2013)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
Andrew Tutt;Mark Robson;Judy E Garber;Susan M Domchek.
The Lancet (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer
A Tutt;M Robson;J E Garber;S M Domchek.
The Lancet (2010)
Hallmarks of 'BRCAness' in sporadic cancers
Nicholas Turner;Andrew Tutt;Alan Ashworth.
Nature Reviews Cancer (2004)
Mutational Processes Molding the Genomes of 21 Breast Cancers
Serena Nik-Zainal;Ludmil B. Alexandrov;David C. Wedge;Peter Van Loo;Peter Van Loo;Peter Van Loo.
The landscape of cancer genes and mutational processes in breast cancer
Philip J. Stephens;Patrick S. Tarpey;Helen Davies;Peter Van Loo;Peter Van Loo.
Landscape of somatic mutations in 560 breast cancer whole-genome sequences
Serena Nik-Zainal;Serena Nik-Zainal;Helen Davies;Johan Staaf;Manasa Ramakrishna.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: